C Elizabeth Caldon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7847311/publications.pdf

Version: 2024-02-01

49 papers	4,391 citations	172457 29 h-index	206112 48 g-index
51 all docs	51 docs citations	51 times ranked	9200 citing authors

#	Article	IF	Citations
1	Cyclin D as a therapeutic target in cancer. Nature Reviews Cancer, 2011, 11, 558-572.	28.4	1,159
2	Partial inhibition of Cdk1 in G₂phase overrides the SAC and decouples mitotic events. Cell Cycle, 2014, 13, 1400-1412.	2.6	773
3	Cell cycle control in breast cancer cells. Journal of Cellular Biochemistry, 2006, 97, 261-274.	2.6	184
4	Targeting CDK2 in cancer: challenges and opportunities for therapy. Drug Discovery Today, 2020, 25, 406-413.	6.4	140
5	Evolution of a molecular switch: universal bacterial GTPases regulate ribosome function. Molecular Microbiology, 2001, 41, 289-297.	2.5	136
6	Estrogen Signaling and the DNA Damage Response in Hormone Dependent Breast Cancers. Frontiers in Oncology, 2014, 4, 106.	2.8	130
7	Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells. Molecular Cancer Therapeutics, 2012, 11, 1488-1499.	4.1	129
8	The androgen receptor is a tumor suppressor in estrogen receptorâ€“positive breast cancer. Nature Medicine, 2021, 27, 310-320.	30.7	122
9	Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer. Cell Division, 2010, 5, 2.	2.4	111
10	Increased Proliferation and Altered Growth Factor Dependence of Human Mammary Epithelial Cells Overexpressing the Gab2 Docking Protein. Journal of Biological Chemistry, 2006, 281, 626-637.	3.4	108
11	Function of the universally conserved bacterial GTPases. Current Opinion in Microbiology, 2003, 6, 135-139.	5.1	105
12	Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer. Endocrine-Related Cancer, 2019, 26, R15-R30.	3.1	96
13	Identification of Functional Networks of Estrogen- and c-Myc-Responsive Genes and Their Relationship to Response to Tamoxifen Therapy in Breast Cancer. PLoS ONE, 2008, 3, e2987.	2.5	85
14	ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer. PLoS Biology, 2012, 10, e1001461.	5.6	74
15	Cell cycle proteins in epithelial cell differentiation: Implications for breast cancer. Cell Cycle, 2010, 9, 1918-1928.	2.6	72
16	Replication timing and epigenome remodelling are associated with the nature of chromosomal rearrangements in cancer. Nature Communications, 2019, 10, 416.	12.8	71
17	Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helixâ€“loopâ€“helix protein Id1. Oncogene, 2005, 24, 381-389.	5.9	66
18	Estrogen Regulation of Cyclin E2 Requires Cyclin D1 but Not c-Myc. Molecular and Cellular Biology, 2009, 29, 4623-4639.	2.3	61

#	Article	IF	Citations
19	Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer. Cell Reports, 2018, 23, 3312-3326.	6.4	61
20	Cell Cycle Machinery:. Advances in Experimental Medicine and Biology, 2008, 630, 189-205.	1.6	52
21	Carious Dentine Provides a Habitat for a Complex Array of Novel Prevotella -Like Bacteria. Journal of Clinical Microbiology, 2004, 42, 5238-5244.	3.9	48
22	Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1. Cell Cycle, 2013, 12, 606-617.	2.6	47
23	BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer. Molecular Cancer Therapeutics, 2013, 12, 1874-1885.	4.1	45
24	MASTL overexpression promotes chromosome instability and metastasis in breast cancer. Oncogene, 2018, 37, 4518-4533.	5.9	45
25	PP1 initiates the dephosphorylation of MASTL, triggering mitotic exit and bistability in human cells. Journal of Cell Science, 2016, 129, 1340-54.	2.0	44
26	Porphyrin-Mediated Cell Surface Heme Capture from Hemoglobin by Porphyromonas gingivalis. Journal of Bacteriology, 2003, 185, 2528-2537.	2.2	42
27	DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrity. Cell Reports, 2021, 36, 109722.	6.4	39
28	MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer. Breast Cancer Research, 2020, 22, 87.	5.0	37
29	Functional characterization of cancer-associated Gab1 mutations. Oncogene, 2013, 32, 2696-2702.	5.9	33
30	19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes. Gynecologic Oncology, 2018, 151, 327-336.	1.4	31
31	Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells. Cell Cycle, 2013, 12, 596-605.	2.6	30
32	The Helix-Loop-Helix Protein Id1 Requires Cyclin D1 to Promote the Proliferation of Mammary Epithelial Cell Acini. Cancer Research, 2008, 68, 3026-3036.	0.9	26
33	Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation. Oncogene, 2008, 27, 126-138.	5.9	25
34	Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Science Advances, 2021, 7, eabh0363.	10.3	23
35	The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. International Journal of Molecular Sciences, 2019, 20, 667.	4.1	19
36	The epigenetic agents suberoylanilide hydroxamic acid and 5-AZA-2â€² deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo. International Journal of Oncology, 2015, 46, 2223-2230.	3.3	17

#	Article	IF	Citations
37	The Antiproliferative Effects of Progestins in T47D Breast Cancer Cells Are Tempered by Progestin Induction of the ETS Transcription Factor Elf5. Molecular Endocrinology, 2010, 24, 1380-1392.	3.7	16
38	Cyclin E2 Promotes Whole Genome Doubling in Breast Cancer. Cancers, 2020, 12, 2268.	3.7	15
39	Cell cycle marker expression in benign and malignant intraductal papillary lesions of the breast. Journal of Clinical Pathology, 2015, 68, 187-191.	2.0	13
40	Label free, quantitative single-cell fate tracking of time-lapse movies. MethodsX, 2019, 6, 2468-2475.	1.6	13
41	Optimizing metastatic-cascade-dependent Rac1 targeting in breast cancer: Guidance using optical window intravital FRET imaging. Cell Reports, 2021, 36, 109689.	6.4	12
42	Mouse Model of Mutated in Colorectal Cancer Gene Deletion Reveals Novel Pathways in Inflammation and Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 819-839.	4.5	11
43	Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition. Npj Breast Cancer, 2021, 7, 111.	5.2	9
44	miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma. Molecular Therapy, 2022, 30, 1119-1134.	8.2	5
45	Cdk2 regulates metastasis suppressor BRMS1. Cell Cycle, 2016, 15, 779-780.	2.6	3
46	Friends and foes: Our evolving understanding of the link between Fbxw7 and p53 in cancer. Neoplasia, 2020, 22, 659-660.	5.3	3
47	High cyclin <scp>E1</scp> protein, but not gene amplification, is prognostic for basalâ€like breast cancer. Journal of Pathology: Clinical Research, 2022, , .	3.0	2
48	MCC Gene Silencing Is a CpG Island Methylator Phenotype-Associated Factor That Predisposes Colon Cancer Cells to Irinotecan and Olaparib. Cancers, 2022, 14, 2859.	3.7	1
49	Editorial: Proceedings From ACCM19: Cell Cycle, DNA Damage Response and Telomeres. Frontiers in Cell and Developmental Biology, 2020, 8, 805.	3.7	0